Ocugen’s Pivotal Juncture: Shareholder Vote on Reverse Split Precedes a Flurry of Gene Therapy Milestones

Ocugen is heading into a defining stretch where corporate governance meets clinical execution. Shareholders will vote on a share consolidation on June 11, just as the biotechnology company gears up to launch rolling regulatory submissions for its lead gene therapy candidate. The twin calendar — one procedural, one scientific — underscores the delicate balance between keeping the stock listed and proving the pipeline’s worth.

The virtual annual meeting, scheduled for June 11, includes a proposal to authorize a reverse stock split in a range of 1:2 to 1:8, with the board retaining discretion over the timing and exact ratio. Only holders of record as of April 20 are eligible to vote. Also on the ballot are the election of two Class III directors, ratification of PwC as auditor, and an advisory vote on executive compensation. The share consolidation is the headline item, giving management flexibility to maintain Nasdaq compliance without altering the fundamental story.

That story remains anchored in three gene therapy programs targeting rare retinal diseases. The most advanced, OCU400 for retinitis pigmentosa, is moving toward a rolling Biologics License Application. Ocugen aims to complete process qualification for the therapy in the second quarter of 2026, then start the BLA submission in the third quarter, beginning with the non?clinical module. The clinical module will follow receipt of topline data. If the timeline holds, a potential approval could come in the fourth quarter of 2027. In the US and Europe, roughly 300,000 people are affected by retinitis pigmentosa.

A second program, OCU410ST for Stargardt disease, has already finished enrollment and dosing in its pivotal GARDian3 study. All 63 participants were recruited in under nine months, ahead of schedule. An interim analysis is expected in the third quarter of 2026, with final phase 2/3 data due in the second quarter of 2027. Stargardt disease, a form of inherited macular degeneration, affects about 100,000 patients in the US and Europe. No product?related serious adverse events have been reported so far.

Should investors sell immediately? Or is it worth buying Ocugen?

A third candidate, OCU410 for geographic atrophy, is also advancing. The phase 3 trial, designed to be registration?enabling, is set to start in the third quarter of 2026 and will enroll up to 300 participants. The study is powered at over 95% to detect a treatment effect. Geographic atrophy is a leading cause of blindness in the elderly, and Ocugen sees its modifier gene therapy approach as a potential one?time treatment.

Financing these parallel development tracks requires deep pockets. Ocugen placed $115 million in convertible notes in early May, carrying a 6.75% coupon and maturing in 2034. The initial conversion price of roughly $2.68 represents a 45% premium over the last reported US closing price before the deal. Part of the proceeds retired an existing Avenue loan, and the remainder extends the company’s cash runway into 2028.

The infusion came just after mixed first?quarter results. Revenue hit $1.53 million, well above the consensus estimate, but the net loss per share of $0.06 was a penny worse than analysts had predicted. Operating expenses totaled $19.4 million, split between $11.3 million in R&D and $8.1 million in general and administrative costs. Net loss for the quarter was $19.18 million, roughly in line with spending.

Analysts remain broadly constructive despite the near?term volatility. Canaccord Genuity analyst Whitney Ijem reaffirmed a buy rating and $12 price target on May 8, citing a convincing efficacy signal in the retinal programs and manageable execution risk around subretinal injection. Oppenheimer initiated coverage with an outperform rating and a $10 target, while Chardan Capital maintains a buy with a $7 target. The stock, trading around €1.28, has lost roughly 17% over the past month but still shows a gain of more than 100% over the past twelve months.

Ocugen at a turning point? This analysis reveals what investors need to know now.

On the commercial front, Ocugen has begun laying the groundwork for eventual launch. In South Korea, the company granted Kwangdong Pharmaceutical exclusive rights to OCU400 in exchange for upfront payments, near?term milestones, and royalties. Additional partnership discussions are likely as the pipeline matures.

The next concrete date is June 11, when shareholders have their say on the reverse split. A green light would give the board a tool to manage share price, but it won’t change the essential calculus: Ocugen must deliver clean clinical data and a timely BLA filing starting in the third quarter. The capital structure vote is a procedural step; the real proof will come from the lab.

Ad

Ocugen Stock: New Analysis - 13 May

Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Ocugen analysis...

en | US67577C1053 | OCUGEN’S | boerse | 69323647 |